RecruitingNCT06408246
Sertraline with guanfacine or placebo for depression and cognitive symptoms
About this title
Read the official source — NCT06408246Medication studyAges 18–60United States
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
- Listed locations
- Palo Alto and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 3, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 162
- Sponsor
- Stanford University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT06408246
- Official title
Show the full official title
Accelerating Cognition-guided Signatures to Enhance Translation in Depression Aim 3: Clinical Cognitive Trial
Recruitment & locations
RecruitingPalo Alto · Chicago
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Stanford University, a university.
Does this study involve medication?
Yes. The study involves medication, including Guanfacine and Sertraline.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
